dc.contributor.author | Opstad, Trine B | |
dc.contributor.author | Pettersen, Alf Å | |
dc.contributor.author | Arnesen, Harald | |
dc.contributor.author | Seljeflot, Ingebjørg | |
dc.date.accessioned | 2015-10-20T10:52:51Z | |
dc.date.available | 2015-10-20T10:52:51Z | |
dc.date.issued | 2011 | |
dc.identifier.citation | Cardiovascular Diabetology. 2011 Dec 05;10(1):110 | |
dc.identifier.uri | http://hdl.handle.net/10852/47010 | |
dc.description.abstract | Background
Increased IL-18 serum levels have been associated with diabetes type 2, metabolic syndrome and the severity of atherosclerosis. The present study investigated the presence and influence of IL-18 genetic variants on gene- and protein expression in stable coronary artery disease (CAD) patients.
Methods
The +183 A/G (rs 5744292), -137 G/C (rs 187238) and -607 C/A (rs 1946518) polymorphisms were determined in 1001 patients with angiographically verified stable CAD, and in 204 healthy controls. IL-18 gene-expression was measured in circulating leukocytes in 240 randomly selected patients. Circulating IL-18 and IL-18 binding protein levels were measured immunologically in all patients.
Results
The +183 G-allele associated significantly with lower serum levels of IL-18 (p = 0.002, adjusted for age, glucose, body mass index and gender) and a 1.13- fold higher IL-18 gene-expression (p = 0.010). No influence was observed for the -137 G/C and -607 C/A polymorphisms. The IL-18 binding protein levels were not influenced by IL-18 genotypes. IL-18 levels were significantly higher in men as compared to women, and in patients with diabetes type 2 and metabolic syndrome compared to those without (p ≤ 0.001, all). The reduction in IL-18 levels according to the +183 G-allele was 3-4 fold more pronounced in diabetes and metabolic syndrome as compared to unaffected patients.
Finally, the +183 AA genotype was more frequent in patients with hypertension (p = 0.042, adjusted for age, body mass index and gender).
Conclusion
The reduction in serum IL-18 levels across increasing numbers of +183G-alleles was especially apparent in patient with diabetes type 2 and metabolic syndrome, suggesting a beneficial GG genotype in relation to cardiovascular outcome in these patients.
Clinical Trial Registration Number
ClinicalTrials.gov: NCT00222261 | |
dc.language.iso | eng | |
dc.rights | Opstad et al; licensee BioMed Central Ltd. | |
dc.rights | Attribution 2.0 Generic | |
dc.rights.uri | http://creativecommons.org/licenses/by/2.0/ | |
dc.title | Circulating levels of IL-18 are significantly influenced by the IL-18 +183 A/G polymorphism in coronary artery disease patients with diabetes type 2 and the metabolic syndrome: an Observational Study | |
dc.type | Journal article | |
dc.date.updated | 2015-10-20T10:52:51Z | |
dc.creator.author | Opstad, Trine B | |
dc.creator.author | Pettersen, Alf Å | |
dc.creator.author | Arnesen, Harald | |
dc.creator.author | Seljeflot, Ingebjørg | |
dc.identifier.doi | http://dx.doi.org/10.1186/1475-2840-10-110 | |
dc.identifier.urn | URN:NBN:no-51159 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/47010/1/12933_2011_Article_435.pdf | |
dc.type.version | PublishedVersion | |
cristin.articleid | 110 | |